Skip to content

A Pilot Study of Virtual Reality and Antigravity Treadmill for Gait Improvement in Parkinson

Effects of Virtual Reality Combined With Antigravity Treadmill Rehabilitation for Gait Improvement of Patients With Parkinson's Disease: a Pilot Study

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04117737
Enrollment
12
Registered
2019-10-07
Start date
2019-09-30
Completion date
2019-12-30
Last updated
2020-01-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gait Disorders, Neurologic, Parkinson Disease

Keywords

Parkinson, Virtual reality, Anti-gravity treadmill, Rehabilitation, Gait disorders

Brief summary

The aim of this study is to improve knowledge about mechanical gait assistance combined with virtual reality efficiency in gait recovery for Parkinson´s patients. It is hypothesised that 12 sessions of 30 minutes each, over a 4 weeks period, of antigravity treadmill rehabilitation combined with virtual reality treatment is effective for increase gait autonomy in patients with Parkinson's disease.

Interventions

OTHERVirtual reality combined with anti-gravity treadmill

The system is composed of three major parts: the treadmill, the antigravity system and the virtual reality system. The treadmill is the base of the device. It is a rounded and concave structure that permits to walk in all direction. For simulate anti-gravity, a harness and pulley system allow to regulate the weight. Finally, the virtual reality system enables participants to simulate an experience of daily life.

Sponsors

Universidad San Jorge
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Masking description

Outcomes assessor was blinded to outcomes values between sessions and to the adherence of participants to the intervention.

Eligibility

Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
No

Inclusion criteria

* Having Parkinson's disease diagnosed by a neurological doctor. * Having an alteration of the gait caused by the neurological disorder. * Being able to have an independent and voluntary walk of 10 meters as minimum. * Height more than 150 cm.

Exclusion criteria

* Being blind. * Medical contraindications for walking. * Being amputee. * Alcohol or drugs abuse. * Other diseases that impedes the intervention.

Design outcomes

Primary

MeasureTime frameDescription
Changes in gait autonomyBaseline and 4-weeksChanges in gait autonomy will be measured by 6-Minutes Walking Test (6MWT). The 6MWT consists of measuring the maximum distance (in meters) that the subject can walk during 6 minutes in a flat surface.

Secondary

MeasureTime frameDescription
Changes in gait speedBaseline and 4-weeksChanges in gait speed will be measured by 10-Meter Walk Test (10MWT). The 10MWT consists of asking the subject to walk a 14m distance on flat area and measure the time spent from meter 2 to meter 12. Time will be measured by a digital chronometer. Gait speed will be calculated in meter per second.
Changes in balance and gait abilityBaseline and 4-weeksChanges in balance and gait ability will be measured by Tinetti scale. The Tinetti test is a simple, reproducible way of assessing the risk of falling in the elderly. This scale is composed of two value, static and dynamic: the test grants a maximum of 16 points for static part (sitting) and 12 point for dynamic (walking) part. Higher is the score, better is the performance.
Changes in quality of lifeBaseline and 4-weeksChanges in quality of life will be measured by by 36-Item Short-Form Health Survey (SF-36). SF-36 assesses 8 physical and mental health domains: 1) Physical Functioning, 2) Social Functioning, 3) Role-Physical, 4) Bodily Pain, 5) Mental Health), 6) Role-Emotional, 7) Vitality, and 8) General Health. For each scale, item scores are coded, summed, and transformed, with final values expressed as a percentage, ranging from 0 (worst health) to 100 (best health).

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026